Aequus Financial Statements From 2010 to 2025
| AQSZF Stock | USD 0 0 25.64% |
Check Aequus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aequus Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Aequus financial statements analysis is a perfect complement when working with Aequus Pharmaceuticals Valuation or Volatility modules.
Aequus |
Aequus Pharmaceuticals OTC Stock Current Valuation Analysis
Aequus Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Aequus Pharmaceuticals Current Valuation | 3.03 M |
Most of Aequus Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aequus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Aequus Pharmaceuticals has a Current Valuation of 3.03 M. This is 99.98% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.98% higher than that of the company.
Aequus Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aequus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aequus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aequus Pharmaceuticals competition to find correlations between indicators driving Aequus Pharmaceuticals's intrinsic value. More Info.Aequus Pharmaceuticals is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aequus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Aequus Pharmaceuticals Financial Statements
Aequus Pharmaceuticals stakeholders use historical fundamental indicators, such as Aequus Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Aequus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aequus Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Aequus Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aequus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Aequus Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 14 people.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Aequus OTC Stock
Aequus Pharmaceuticals financial ratios help investors to determine whether Aequus OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aequus with respect to the benefits of owning Aequus Pharmaceuticals security.